ZNF3

Across TCGA pan-cancer cohorts, ZNF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF3 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where ZNF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.995	0.485	.003	12	view →
PDAC	OS	Quartile	II,III,IV	0.345	0.784	.025	4	view →
CCRCC	DFS	Median	All	0.642	0.860	.022	3	view →
LSCC	DFS	Median	All	0.987	0.890	.021	3	view →
UCEC	DFS	Median	All	1.000	0.934	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF3–LUAD (DFS)

Open the LUAD breakdown →